Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

JAMA Network Open(2025)10.1001/jamanetworkopen.2024.53588Source: DataRank Database

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma is a research paper published in JAMA Network Open (2025). On theSindex it has a DataRank of 0.892. It has been cited 36 times, with 36 citing works in its 1-hop citation network.

N/A

0.892DataRank · unranked

Scored on demand from live citation data

Open Access36 citations · 36 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 17.53)OA: goldTopics (78)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 61%Citation Network 39%

Base Score Contribution

0.542

From this paper's citation signal

Citation Network Contribution

0.351

From 17 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 36 citers.

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic Cancer
Clinical Cancer Research20267 citations36 referencesContributes 0.058
Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma
Pancreatology20253 citations26 referencesContributes 0.053
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
BMJ Open Gastroenterology20255 citations34 referencesContributes 0.053
The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival
Annals of Surgery20255 citations43 referencesContributes 0.042
Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence
International Journal of Molecular Sciences20263 citations47 referencesContributes 0.029

Authors (8)

Matthew Shaw ORCID,Zachary Rubnitz,Jarrod Smith ORCID,Heloisa P. Soares ORCID,Chris Nevala-Plagemann ORCID

Live enrichment

PubMed:39777438 OpenAlex:https://openalex.org/W4406143999

National Institutes of Health

Grant: 3P30CA042014-30S2

Cancer Center Support Grant

NCI NIH HHS

Grant: P30 CA042014

FWCI

17.53

Citation Percentile

1.0%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2828753/norton_2025_oi_241499_1734984844.55332.pdf

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2828753/norton_2025_oi_241499_1734984844.55332.pdf

journalhttps://doi.org/10.1001/jamanetworkopen.2024.53588

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39777438

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11707629

Fields of Study

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentNeuroendocrine Tumor Research Advances03 medical and health sciences0302 clinical medicineHumansMalePancreatic NeoplasmsFemaleProto-Oncogene Proteins p21(ras)AgedRetrospective StudiesMutationMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalTreatment OutcomeAdenocarcinomaFluorouracilLeucovorinOxaliplatinIrinotecanAged, 80 and overAdultNeoplasm Metastasis

MeSH Terms

IrinotecanOxaliplatinAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsLeucovorinFemaleFluorouracilHumansMaleMiddle AgedMutationNeoplasm MetastasisPancreatic NeoplasmsRetrospective StudiesProto-Oncogene Proteins p21(ras)Treatment OutcomeCarcinoma, Pancreatic Ductal

Keywords

KRASMedicineInternal medicineOncologyHazard ratioPancreatic cancerProportional hazards modelRetrospective cohort studyAdenocarcinomaCohortCancerColorectal cancerConfidence intervalMaleAged, 80 and overAdultLeucovorinMiddle AgedIrinotecanPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)OxaliplatinTreatment OutcomeMutationAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFluorouracilNeoplasm MetastasisOriginal InvestigationAgedRetrospective StudiesCarcinoma, Pancreatic Ductal

Sustainable Development Goals

SDG 0: Good health and well-being